Yuri Teranishi-Ikawa
Company: Chugai Pharmaceuticals
Job title: Principal Scientist
Seminars:
Delving into Chugai Pharmaceutical’s Multidimensional Optimization Process to Improve Both the Therapeutic Potential & the Manufacturability 4:00 pm
Exploring FAST-Ig™, designed for efficient production of bispecific antibodies and ACTFc®, to improve antibody pharmacokinetics Applying these unique technology platforms to NXT007, a next-generation version of emicizumab for hemophilia A Discussing future directions for creating novel bispecific antibodies and beyondRead more
day: Day One